Capital Realm Financial Holdings Group Limited released an announcement on 26 November 2025 regarding a change in the use of proceeds from its rights issue. The rights issue initially generated net proceeds of approximately HK$154.5 million, which were originally allocated as follows: about HK$72.0 million for bond repayment, HK$68.1 million for future investments, and HK$14.4 million for general working capital.
According to the announcement, approximately HK$147.2 million of these funds have been utilized to date, leaving around HK$7.3 million. The company decided to reallocate part of the remaining proceeds to invest in the medical device industry as part of its strategy to explore diversified opportunities. Under the revised allocation, a portion of the funds previously designated for bond repayment and general working capital has been rechanneled to this new investment plan. Management expects to fully utilize the remaining HK$7.3 million by 31 March 2026.
The company emphasizes that the nature of its business remains unchanged and advises shareholders and potential investors to exercise caution when dealing in its shares.
Comments